By
Trending Posts
Will Novartis’s $12 Billion Avidity Deal Ignite a…
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine…
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions of experiments to…
Could the Algen Biotechnologies – AstraZeneca $555 Million…
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and AstraZeneca marks a…
Can Takeda and Nabla Bio’s $1 Billion AI…
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Could Cohere’s New Paris Office Accelerate AI Adoption…
Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large language models and…
Could Aiforia and Siemens Healthineers Transform Digital Pathology…
Key Insights: Strategic Partnership to Expand AI Pathology Aiforia Technologies Plc announced a major collaboration with Siemens Healthineers…
Can Ant Group’s AQ AI Health App Redefine…
Key Highlights Expanding AI Access in HealthcareSince its launch in June 2025, Ant Group’s AQ AI Health App…
Can GHX’s AI-Driven Supply Chain Solutions Transform How…
Key Highlights AI reshaping healthcare supply chains: Unlike retail or tech, healthcare requires flawless delivery—any delay can directly…
Is Stanford’s MedAgentBench Setting the New Gold Standard…
Key Highlights AI benchmarking moves beyond knowledge tests: Unlike earlier evaluations that focused on exams like the USMLE,…
Trending Posts
Latest Stories
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) —…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions…
Could the Algen Biotechnologies – AstraZeneca $555 Million AI-Driven Drug-Discovery Pact Redefine How Immunology Therapies Are Developed?
Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and…
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to…
Gallery
